摘要
肠促胰岛素包括胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)和葡萄糖依赖性促胰岛素释放多肽(Glucose-dependent insulinotropic polypeptide, GIP)两种分子,能够在肠道摄入食物后通过血糖依赖机制促进胰岛素的分泌。胰高血糖素样肽-1受体激动剂(Glucagon-like peptide-1 receptor agonists, GLP-1RAs)类药物凭借其良好的降糖活性、显著的体重控制作用以及明显的心血管收益在糖尿病的治疗中占据重要地位,基于另一肠促胰岛素GIP的疗法能否在糖尿病患者中发挥降糖作用仍不确定。GIP/GLP-1双重受体激动剂在临床试验中展现出了较好的治疗效果,针对糖尿病这一复杂的综合代谢性疾病,单分子多重受体激动剂似乎更具有潜力。文章介绍了基于肠促胰岛素的已上市药物,综述近年来处于临床试验阶段的基于肠促胰岛素治疗糖尿病的分子,以期为基于肠促胰岛素治疗糖尿病提供更多研究思路。
Incretin, including GLP-1 and GIP,which could be promoted insulin secretion through a glucose-dependent mechanism after food was ingested in the gut.GLP-1R agonists have played an important role in the treatment of diabetes with their good hypoglycemic activity, weight control ability and obvious cardiovascular benefits, but uncertainty exists as to whether the therapy based on another incretin GIP could exert curative effect.A dual GLP-1 and GIP receptor agonist has demonstrated its good therapeutic effect in clinical trials.To treat a complex and comprehensive metabolic disease like diabetes, single-molecule multi-target agonists may have superior efficacy.The available drugs based on incretin was introduced, and the molecular therapy of diabetes based on incretin in clinical trials was reviewed in recent years, in order to provide more research ideas for the treatment of diabetes based on incretin.
作者
吴宇欣
田浤
高向东
WU Yu-xin;TIAN Hong;GAO Xiang-dong(l.Jiangsu Key Laboratory of Druggability of Biopharmaceuticals,China Pharmaceutical University,Nanjing 210009,China;School of Life Science and Technology,China Pharmaceutical University,Nanjing 210009,China)
出处
《药物生物技术》
CAS
2022年第6期624-628,共5页
Pharmaceutical Biotechnology
